Dronedarone Hydrochloride API

Name	Dronedarone hydrochloride
Chinese name	盐酸决奈达隆
Cas Number	141625-93-6
Source	India
Qualifications	USDMF/-/-/-/-

Dronedarone hydrochloride is an antiarrhythmic drug developed by Sanofi-Aventis of France. It was approved by the U.S. Food and Drug Administration (FDA) in July 2009. It is also the first antiarrhythmic drug approved in the European Union in 10 years. New medicine for arrhythmia. Dronedarone hydrochloride can inhibit various ion channels of cardiomyocytes and prolong the APD phase, but the degree of inhibition of different channels is different. Compared with amiodarone, the gold standard anti-arrhythmic drug, dronedarone hydrochloride does not contain iodine in its chemical structure and is less lipophilic. Phospholipids will not deposit in the lungs after taking it. Therefore, adverse reactions outside the cardiovascular system are better than amines. Less iodone. Studies have shown that dronedarone hydrochloride can prolong the RR and QT intervals of cardiomyocytes, and the ventricular APD50 and APD90 can be prolonged by 20% and 49%, respectively. The above effects of dronedarone at the same dose are stronger than that of amiodarone. Both the 2011 US version and the 2010 European version of the Atrial Fibrillation Guidelines recommend dronedarone for the treatment of atrial fibrillation. In 2018, the sales of dronedarone hydrochloride in foreign markets were approximately 2.73 billion yuan. From 2015 to 2018, the market size of commonly used antiarrhythmic drugs in China continued to increase. In 2018, the overall sales reached 536 million yuan.

Hot Tags: dronedarone hydrochloride api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Bivalrudine API, Troxagliptin Succinate API, Paliperidone API, Itraconazole Hydrochloride API, Vardenafil API, Oseltamivir Phosphate API

• Previous: Ferrous Sulfate API
• Next: Opemifene API